Several clinical studies and a retrospective case–control study have shown that denosumab (RANKL inhibitor) may reduce local recurrence after surgery [24], but there is no conclusive evidence for the use of denosumab in the recurrence of GCT-ST. Here, TNFSF11 is linked to granular cell tumor.